Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-22-005424
Filing Date
2022-02-09
Accepted
2022-02-09 16:30:12
Documents
1
Period of Report
2022-01-31

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3656
  Complete submission text file 0000899243-22-005424.txt   5298
Mailing Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139 617-229-5872
Epizyme, Inc. (Issuer) CIK: 0001571498 (see all company filings)

EIN.: 261349956 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022
Business Address C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022 212-883-0200
Royalty Pharma Investments 2019 ICAV (Reporting) CIK: 0001909645 (see all company filings)

State of Incorp.: L2 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-35945 | Film No.: 22607633